Comparison · NCT02006121-sae
Apomorphine Hydrochloride vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Apomorphine Hydrochloride vs Placebo: serious adverse events. Trial comparisons, record NCT02006121-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02006121-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.235 | 0.162 | 0.328 | wilson | |
| Risk in group 2 | 0.0377 | 0.0104 | 0.128 | wilson | |
| Risk difference, group 1 minus group 2 | 0.197 | 0.0813 | 0.294 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 6.22 | 1.52 | 25.4 | log | |
| Odds ratio, group 1 over group 2 | 7.82 | 1.77 | 34.6 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Apomorphine Hydrochloride than on Placebo | 5.08 | 3.4 | 12.3 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Apomorphine Hydrochloride | Apo-go® Apomorphine hydrochloride 5 mg/ml solution for infusion in pre-filled syringe | 23 | 98 | EG000 |
| Group 2 | Placebo | Placebo: saline infusion Sodium chloride 9 mg/ml | 2 | 53 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Adverse Events were collected during the double-blind and open label phases of the study. 98 patients were exposed to at least one dose of apomorphine with a cumulative person time of 4081 weeks of exposure. The range of exposure to apomorphine was 37-464 days (mean 397 days). In addition, 53 patients (44 of whom went onto apomorphine in the open label phase) were exposed to placebo treatment in the double blind phase with a maximum 12 weeks of exposure.
Source ClinicalTrials.gov
Trial
- Title
- Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease
- NCT number
- NCT02006121
- Phases
- PHASE3
- Conditions
- Parkinson's Disease
- Interventions
- Apomorphine hydrochloride, Placebo
- Lead sponsor
- Britannia Pharmaceuticals Ltd.
- Results first posted
- 2019-07-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02006121?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02006121-sae